Figure 1

UV spectra of absorbance of WTavidin, OXavidin and $OXavidin_{HABA}$




Figure 2

SEC HPLC analysis of $OXavidin_{HABA}$ compared to OXavidin and WTavidin




Figure 3

Tissue permanence of ^{125}I-avidins after i.m. injection

Figure 3a




Figure 3b




Figure 3c




Figure 3d




Figure 3e




Controlateral Limb
WTavidin
OXavidin
% / ID/100 mg
0.50
0.45
0.40
0.35
0.30
0.25
0.20
0.15
0.10
0.05
0.00
1
24
48
hours

Figure 4

Long term permanence of Oxavidin$_{HABA}$ compared to WTavidin in a treated tissue






Figure 5

Tissue permanence of $OXavidin_{HABA}$ compared to WTavidin and PEGavidin




Figure 6

Immunofluorescence of WTavidin or $OXavidin_{HABA}$ in treated tissue 24 hours after injection






Figure 7

Tissue permanence of ^{111}InST2210 i.v. injected 48 hours after tissue avidination

a



b c



d e




Figure 8

Tissue permanence of the complex $Oxavidin_{HABA}$/ST2210 compared to WTavidin/ST2210




Figure 9

Brain permanence of $OXavidin_{HABA}$ compared to WTavidin

